Abbott Laboratories (ABT) Stock Forecast & Price Target

Abbott Laboratories
Bull Case

Here are some ways that investors could benefit from investing in Abbott Laboratories:

• Abbott Laboratories recently beat analyst expectations in its most recent quarterly report, delivering earnings per share of $1.31 against a consensus estimate of $1.28, while also generating revenue of $12.59 billion, which exceeded the projected $12.52 billion and represented a 13.0% year-over-year increase.
• The company maintains a strong dividend profile with a current yield of 2.46%, and it recently declared a quarterly dividend of $0.63 per share, which is scheduled to be paid on November 16th to investors of record on October 15th.
• Wall Street analysts hold a positive outlook on the stock, with a consensus rating of Moderate Buy and a target price of $119.50, which suggests significant upside potential from the current stock price of $104.79.
• Abbott Laboratories is recognized as a key player in the emerging field of closed-loop neurostimulation, a technology that allows bioelectronic medicine devices to interact with neural signals to modulate treatment in real time, complementing its existing portfolio in cardiac and diabetes care.
• The company continues to innovate in its nutritional segment, recently debuting Ensure Max Protein Powder with Creatine and HMB, which demonstrates its ability to adapt its product offerings to meet evolving consumer health needs.